Section Arrow
KYMR.NASDAQ
- Kymera Therapeutics
Quotes are at least 15-min delayed:2026/06/01 15:04 EDT
Regular Hours
Last
 79.64
-1.78 (-2.19%)
Day High 
80.71 
Prev. Close
81.42 
1-M High
89.46 
Volume 
252.03K 
Bid
79.44
Ask
79.64
Day Low
77.2 
Open
80.66 
1-M Low
76.87 
Market Cap 
6.70B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 80.55 
20-SMA 82.36 
50-SMA 83.33 
52-W High 103 
52-W Low 36.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.58/-4.49
Enterprise Value
6.77B
Balance Sheet
Book Value Per Share
18.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
39.21M
Operating Revenue Per Share
0.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.9048+0.497+121.87%-- 
OTLKOutlook Therapeutics0.8676+0.1376+18.85%-- 
RXRXRecursion Pharmaceuticals3.845+0.255+7.10%-- 
GNTAGenenta Science SpA1.66+0.63+61.17%-- 
IBRXImmunityBio7.16-0.36-4.79%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.